LY-411575: Potent γ-Secretase Inhibitor with IC50 0.078 nM for Alzheimer's and Cancer Research

Executive Summary: LY-411575 is a highly selective γ-secretase inhibitor with sub-nanomolar potency (IC50 = 0.078 nM in membrane assays) that efficiently blocks cleavage of amyloid precursor protein (APP) and Notch receptors, reducing amyloid beta (Aβ) peptide production implicated in Alzheimer's pathology (APExBIO). The compound also inhibits Notch S3 cleavage (IC50 = 0.39 nM), modulating oncogenic pathways relevant to cancer research. In vivo, LY-411575 reduces brain and plasma Aβ levels in transgenic CRND8 mice at oral doses of 1–10 mg/kg. Its solubility profiles (≥23.85 mg/mL in DMSO, ≥98.4 mg/mL in ethanol with sonication) and formulation compatibility allow integration into advanced research workflows. These properties make LY-411575 a gold-standard reference for mechanistic studies in neurodegeneration and oncology (Hexa-His).

Biological Rationale

Alzheimer's disease (AD) is characterized by the accumulation of amyloid β (Aβ) peptides, especially Aβ42, in extracellular plaques, leading to neurodegeneration and cognitive decline (Satir et al., 2020). Aβ peptides are generated by sequential cleavage of amyloid precursor protein (APP) by β-secretase (BACE) and γ-secretase. While BACE initiates cleavage, γ-secretase finalizes Aβ production; both enzymes are thus validated therapeutic targets (Satir et al., 2020). In addition, γ-secretase mediates Notch receptor activation, a pathway involved in cell fate, proliferation, and cancer processes. Inhibition of γ-secretase offers dual utility: reducing neurotoxic Aβ generation for AD research and modulating Notch signaling in oncology (Z-VEID-fmk).

Mechanism of Action of LY-411575

LY-411575 is a small-molecule, non-peptidic inhibitor that binds the active site of presenilin, the catalytic subunit of the γ-secretase complex. This binding blocks intramembrane cleavage of type-I membrane proteins, including APP and Notch substrates (APExBIO). In cell-based assays, LY-411575 exhibits an IC50 of 0.082 nM for γ-secretase inhibition and 0.39 nM for Notch S3 cleavage, indicating high selectivity and potency. By halting Aβ generation, it models disease-modifying interventions in AD research. Inhibition of Notch signaling by LY-411575 induces apoptosis in tumor cells, modulating cancer microenvironments (Kanamycin Sulfate). The dual blockade of APP and Notch cleavage is central to its research applications in neurodegeneration and oncology.

Evidence & Benchmarks

• LY-411575 inhibits γ-secretase with an IC50 of 0.078 nM in membrane-based assays (APExBIO datasheet: https://www.apexbt.com/ly-411575.html).
• In cell-based models, LY-411575's IC50 for γ-secretase inhibition is 0.082 nM (APExBIO, datasheet).
• LY-411575 reduces Notch S3 cleavage with an IC50 of 0.39 nM, effectively modulating Notch signaling (APExBIO).
• Oral administration of LY-411575 (1–10 mg/kg) in CRND8 mice reduces brain and plasma Aβ levels in vivo (APExBIO, datasheet).
• γ-Secretase inhibition blocks APP cleavage, thereby reducing Aβ40 and Aβ42 production, as validated in transgenic mouse models (Satir et al., 2020).
• Notch pathway inhibition by LY-411575 results in apoptosis in tumor cells, implicating the compound in cancer pathway research (Z-VEID-fmk).
• LY-411575 is insoluble in water but highly soluble in DMSO (≥23.85 mg/mL) and ethanol (≥98.4 mg/mL with sonication), supporting diverse assay protocols (APExBIO).
• γ-Secretase inhibitors, including LY-411575, have been used to model disease mechanisms, but broad substrate specificity can result in on-target toxicities, as seen in clinical trials (Satir et al., 2020).

Compared to the related article here, this review provides updated benchmarks and clarifies in vivo dosage-response relationships for LY-411575.

Applications, Limits & Misconceptions

LY-411575 is widely used in Alzheimer's disease models to dissect the role of Aβ production and deposition. Its potent Notch pathway inhibition supports research in leukemia, Kaposi's sarcoma, and other cancers where Notch signaling is dysregulated. The compound is also employed in cell viability and pathway modulation assays to elucidate molecular mechanisms of apoptosis.

• Translational models: LY-411575 enables in vivo and in vitro studies on the impact of γ-secretase inhibition on disease progression (Epidermal Growth Factor Receptor).
• Mechanistic studies: Used for precision modulation of amyloid beta production and Notch signaling (AS-605240).
• Workflow reliability: High solubility and stability under defined conditions facilitate reproducible experimental setups.

Common Pitfalls or Misconceptions

• Not a BACE inhibitor: LY-411575 does not target β-secretase and thus cannot be used to study BACE-specific mechanisms (Satir et al., 2020).
• Not water-soluble: The compound is insoluble in water; improper dissolution may affect assay outcomes.
• Not selective for a single pathway: γ-Secretase processes multiple substrates, so off-target effects (e.g., gastrointestinal toxicity) are possible in vivo.
• Not a therapeutic agent: LY-411575 is for research use only and not approved for clinical interventions.
• Long-term solution storage is discouraged: Fresh preparation is needed due to instability of solutions, especially in DMSO or ethanol.

Workflow Integration & Parameters

LY-411575 is supplied as a solid, stable at −20°C. For in vitro studies, a 10 mM stock solution in DMSO is standard; warming or sonication enhances dissolution. For in vivo administration, it is formulated with polyethylene glycol, propylene glycol, ethanol, and methylcellulose. Oral dosing in mice (1–10 mg/kg) has demonstrated robust reduction of Aβ levels. Solutions should be prepared fresh and used promptly to maintain potency. For pathway modulation or apoptosis induction, dose-response curves are recommended to optimize selectivity and minimize off-target effects. Refer to the A4019 kit product page for detailed protocols.

This article extends guidance found in this workflow resource by providing quantitative solubility data and explicit storage recommendations.

Conclusion & Outlook

LY-411575, as offered by APExBIO, is a benchmark γ-secretase inhibitor for mechanistic and translational research in Alzheimer's disease and oncology. Its sub-nanomolar potency, dual pathway inhibition, and validated in vivo efficacy support advanced disease modeling. However, broad substrate specificity and off-target liabilities require careful experimental design. Ongoing research focuses on improving pathway selectivity and leveraging LY-411575 for preclinical discovery. For updated references and validated workflows, consult the official LY-411575 product page.

For a comparative analysis of γ-secretase inhibitors, see this related article, which this review updates with clarified solubility, selectivity, and workflow integration parameters.